🫣 Just hours after Lykos announced it was laying off 75% of its employees, Max Bayer interviewed the CEO about the company's challenges and the cuts. endpts.com/qa-lykos-just-…

Excited to share I'm leading Endpts' first AI Day! I'll be moderating conversations with people like ... --> David Baker @ UW's IPD --> Alex Rives, ex-Meta/EvoScale --> David Reese, Amgen's CTO Oct. 16 — registration for the free(!) event is now open: events.endpts.com/aiday24

👀 news.bloomberglaw.com/health-law-and…

Endpoints News In the meantime, Endpoints is hiring! Specifically a UK-based senior biopharma journalist to help lead our early coverage. This is a great newsroom that keeps getting better. Happy to answer any questions or just to chat :) ats.rippling.com/endpointsnews/…

The silver lining: We're hiring for a stellar UK-based reporter to join us! You'd join a fabulous & growing London-based team and play a key role in an ambitious, fun newsroom DM me if you're curious to learn more: ats.rippling.com/endpointsnews/…

We're heartbroken the great Amber Tong is leaving us, but excited to keep reading her byline❤️ And... WE'RE HIRING! They're big shoes to fill, but we are on the hunt for a senior journalist to join our amazing team in London. Applications are open! ats.rippling.com/endpointsnews/…

I am seeing this observational study about GLP-1s reducing death all over the place, and want to note here why I am pretty skeptical of the results. I'd bet there would be an effect on overall mortality, but I doubt it would be this big. The first reason is that we have

Matthew Herper Agree that this proportionate reduction is highly unlikely. The absolute reduction from 2.0% to 0.2%, or 1.8/100, over 5-years with more potent GLP-1 drugs may not be so far off, but it'll take dedicated long term RCTs to prove it.

Went to the orthopedist yesterday about a sports injury. They told me that there's an injection that's proven to be about 70% effective, and that the placebo was about 50% effective. It's not covered by insurance, and costs $1,000. Quiz: What's the price of the placebo?

Keep coming back to this excellent interview with Tony Dunn (GSK CSO) and mentally revisiting how tactical differences in pivotal trial design, even among *structurally similar* DCs, can massively influence commercial success (e.g., Keytruda vs Opdivo). endpts.com/qa-gsk-cso-ton…

NEW: A moment of truth is coming for Recursion Max Gelman & I dove into what imminent clinical data could mean for $RXRX and for the broader AI bio field: endpts.com/recursion-near…

❤️❤️❤️❤️❤️❤️📰📰📰📰📰📰

I spoke with UpScript, the telehealth co behind Pfizer's DTC site and others. One thing I learned: Most patients get the drug they came for. “There's clearly a bias toward what the patient wants, and that's helpful to pharma,” CEO Peter Ax told me. reports.endpts.com/107e23d7/ea775…

Exclusive: Bain Capital gathers ~$3 billion for its fourth life sciences fund after handful of recent M&A exits ~$1.1 billion larger than its third haul from 2021 Boston-based firm has backed > 70 biotechs & other startups in eight years Endpoints News endpts.com/exclusive-bain…

Don't miss this great story that dives into the science in the way only Ryan Cross the Science Boss does on the next steps for a potential male contraceptive therapy Now in the hands of a biotech called Contraline: endpts.com/exclusive-a-ma…

🏆For the last few months, our team at Endpoints News has been looking over dozens of new hashtag#startups to find the ones we think are pursuing the most interesting scientific ideas, backed with the right financing and the smart leadership that can create the #biotech breakthroughs of